Alternatives to 9amHealth

FDA warning letter #728279 (Jun. 2026), which names tryeden.com. Read live on 2026-08-26, the GLP-1 page prices compounded semaglutide at $99 a month and compounded tirzepatide at $199 — and the asterisk under both figures is the part that changes the math. It reads: price includes medication only, an active Eden Membership is required at $39 for the first month and $99 a month thereafter, and medication is not available without a membership. So this is two line items, not one, and the second one is not next to the number on the page. What Eden does give you is range: brand Zepbound, Ozempic and Mounjaro at $1,399 a month and Wegovy at $1,695, each on its own product page marked In Stock, alongside the compounded lane. It says it serves GLP-1 programs in all fifty states, and its "same price at every dose" policy means titrating up does not raise the medication line. Cancellation is self-serve in the portal, though the Terms want 48 hours' notice before a renewal and make charges non-refundable once an order is fulfilled.

Pallas Health removes the two things that usually cost a working parent the most time: it publishes every price before intake, and it runs care asynchronously in 43 of 50 states, so there's no video appointment to wedge into a workday. Compounded semaglutide averages about $199 a month and tirzepatide $299, and unusually the genuine FDA-approved pens sit alongside them — Zepbound $1,069, Ozempic $1,299, Wegovy and Mounjaro $1,349 — all cash-pay from the same clinician. The price is flat at every dose, so a titration never produces a surprise bill, and the plan figure already contains the clinician, dose adjustments, check-ins and messaging with no membership fee. Its cancellation terms are unusually concrete: cancel free through the portal, keep access to the end of the paid period, full refund if a clinician declines you, and a $5 processing fee on a qualifying refund. The trade-offs are that billing lands every 12 weeks in $597 and $897 blocks rather than monthly, the compounding pharmacy is never named, and insurance is never billed.

It prices Ozempic and Zepbound at $1,399 and $1,599, which almost nobody here does. The compounded line is “from” $49 — under a dated sale, and billed every four weeks.

AskRx solves the pricing question most of this page leaves open, and creates a different one. Its care fee is itemized in its own footnote — $90/month physician visit, $10/month fulfilment, $100 total — and the medication is billed separately through its own pharmacy, at cost, with both halves shown at checkout. If you have ever wondered how much of a blended monthly price is the drug and how much is margin, this is the provider that answers it. It is FDA-approved only ('No compounded meds'), so the options are the Wegovy pen, the Wegovy pill, Zepbound in pen or KwikPen form, and Foundayo, the oral tirzepatide. All 50 states, board-certified physicians with obesity-medicine training, unlimited messaging, monthly titration, cancel anytime. Two logistics notes that matter on a workday. First, $100 is a floor: no medication price is published, so your real monthly total is unknown until checkout and depends on coverage. Second — and read this one if scheduling is your constraint — 'video visits available in select states' means the async route is not universal here, so confirm your own state before assuming you can do this without a call.

A no-membership-fee, quarterly-billed program — $167/mo semaglutide, $267/mo tirzepatide — bundling a GLP-1 fitness app, meal plans, and 1-on-1 nutrition coaching that most compounded-only competitors don't offer. It also publishes its own named comparison against Ro, Mochi Health, TrimRx, and Hims, an unusually direct move for this category.

The insurance-and-brand heavyweight: a WeightWatchers-run membership that routes you toward FDA-approved product and insurance coverage, with a video visit required in some states — the membership fee and the medication bill are two separate charges.

One public number and a great deal of small print. Read live on 2026-08-26, the homepage says "Starting at $269" for compounded semaglutide and tirzepatide, and neither molecule is priced separately anywhere a reader can reach before the quiz. The footnote matters more than the figure: it says the price is paid upfront in full, that the actual price depends on the product and subscription plan you buy, and that the introductory pricing applies only to new customers on the compounded ORAL semaglutide plan — so the cheapest advertised route is a pill, not the weekly injection most readers are shopping for. The banner reading Get $140 Off Today is a discount amount rather than a price, and at least one industry directory has misread it as a $140 introductory rate. Where TellHerDoc is unusually good is disclosure of everything except price: it serves all fifty states, names its medical team and four partner pharmacies, and publishes the seven jurisdictions where a live video consultation is legally required. Where it is unusually blunt: all sales are final.

Compounded semaglutide at $99 a month and tirzepatide at $149, with the provider visit, two-day shipping and injection supplies all included — genuinely cheap for what is in the box. The catch is in what 'no subscription, ever' actually means here. Those rates are six-month programs, paid as one payment up front. The shortest commitment on offer is three months at $165 a month, and maintenance afterwards runs $199. There is no month-to-month option at all, so the flexibility the phrase implies is the opposite of what is on sale. It also names no company anywhere — an address in Dallas and a phone number, but no legal entity.

From $149 semaglutide, $179 tirzepatide, one bundled price, flat at every dose, all 50 states and D.C. The price buys four weeks — stated in its own terms — and requires a three-month plan, a condition shown in the funnel but not on the homepage cards. The month-to-month tier sits behind the intake and is not published. FDA screen clean against a passing control.